Immunotherapy in urothelial carcinoma of the bladder: Therapeutic advances in 2023
Type de matériel :
TexteLangue : français Détails de publication : 2023.
Ressources en ligne : Abrégé : Immunotherapy, in particular immune checkpoint inhibitors, has recently become part of the standard clinical arsenal against bladder urothelial carcinoma—all the more so since systemic therapy has seen minimal progress in the past 20 years. Since the initial approval of immunotherapy as second-line treatment in platinum refractory patients, new strategies have been evaluated to improve patients’ prognoses. In this review, we summarize advances in immunotherapy agents to treat urothelial carcinoma of the bladder.
Nous n'avons pas d'exemplaire de ce document
35
Immunotherapy, in particular immune checkpoint inhibitors, has recently become part of the standard clinical arsenal against bladder urothelial carcinoma—all the more so since systemic therapy has seen minimal progress in the past 20 years. Since the initial approval of immunotherapy as second-line treatment in platinum refractory patients, new strategies have been evaluated to improve patients’ prognoses. In this review, we summarize advances in immunotherapy agents to treat urothelial carcinoma of the bladder.
Réseaux sociaux